azeliragon

Ligand id: 8317

Name: azeliragon

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 14
Topological polar surface area 39.52
Molecular weight 531.27
XLogP 9.44
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

References
1. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. (2014)
Effect of TTP488 in patients with mild to moderate Alzheimer's disease.
BMC Neurol14: 12. [PMID:24423155]
2. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J et al.. (2003)
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
Nat. Med.9 (7): 907-13. [PMID:12808450]
3. Mjalli A, Andrews R, Shen J, Rothlein R. (2005)
Rage antagonists as agents to reverse amyloidosis and diseases associated therewith.
Patent number: US20050026811 A1. Assignee: Mjalli A, Andrews R, Shen J, Rothlein R. Priority date: 20/05/2003. Publication date: 03/02/2005.
4. Saito S, Ihara M. (2014)
New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy.
Front Aging Neurosci6: 290. [PMID:25368578]
5. TransTech Pharma. 
Azeliragon (TTP488).
Accessed on 15/04/2015. Modified on 15/04/2015. http://www.ttpharma.com, http://www.ttpharma.com/TherapeuticAreas/AlzheimersDisease/Azeliragon/tabid/123/Default.aspx